Journal reading

Long-term prescribing of new oral anticoagulants

Warfarin and the new oral anticoagulants are licensed for non-valvular atrial fibrillation and venous thromboembolism. The choice of anticoagulant depends on the characteristics of the patient and the medicine.

  • Cost: free
START NOW
Long-term prescribing of new oral anticoagulants

Paul KL Chin, Aust Prescr 2016;39:200-4

 

 

CPD Points

This activity should take approximately 1 hour to complete. It can be included in a pharmacist’s CPD Plan for either one Group 1 credit or, on successful completion of the assessment activity, two Group 2 credits. Pharmacists should self-record this activity for CPD purposes.

Pharmacy Competency Standards

  1. 1.4 Manage quality and safety
  2. 4.2 Consider the appropriateness of prescribed medicines
  3. 7.1 Contribute to therapeutic decision making
  4. 7.2 Provide ongoing medication management
 

About

This activity has been designed to take around 1 hour to complete - this is based on reading the article from an issue of Australian Prescriber and completing a quiz. You will be provided with immediate feedback on your answers and a certificate of completion will be available for you to download for self-reporting purposes.

 

Learning objectives

  1. Define circumstances where warfarin would be more appropriate than the new oral anticoagulants.
  2. Comprehend the pharmacokinetics of the new oral anticoagulants.
  3. Define factors that affect the dose of the new oral anticoagulants.
  4. Identify potential drug interactions with the new oral anticoagulants.
  5. Relate what monitoring is required with the new oral anticoagulants.